One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Product mismatch in the original source: the heading says INVOKANA but the body describes INVOKAMET. The complete original statement is preserved; do not apply its combination-product instructions to single-agent canagliflozin.
The handbook retains normal dosing above GFR 60, limits established treatment to 100 mg daily in the 45-60 range, and advises against initiation below eGFR 60 and use below 45. It advises avoidance during the listed replacement modalities and describes canagliflozin as not dialysed. These older cutoffs do not replace the current INVOKANA label.
general-canagliflozin:rdh5-161-1 · Source locator: Renal impairment; renal replacement; Other information
This cross-check is for single-agent canagliflozin, not the mixed INVOKANA/INVOKAMET original statement.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=general-canagliflozin&s1=rdh5-161&h1=7abaebe9614742cae4b339523d1a69e2c215fab6d3d646f715e1cf61b3b38202